July 30, 2020

IBRI IN THE NEWS: IBRI Technologies Lead to Handheld Analyzing Device

Indianapolis - The Indiana Biosciences Research Institute (IBRI) is marking a milestone: the team is licensing its first technology, and as a result, giving birth to a startup based in...

July 25, 2020

IBRI RESEARCH PUBLISHED: Targeting Polyamine Biosynthesis to Stimulate Beta Cell Regeneration in Zebrafish

Abstract Type 1 diabetes (T1D) is a disease characterized by destruction of the insulin-producing beta cells. Currently, there remains a critical gap in our understanding of how to reverse...

July 01, 2020

IBRI RESEARCH PUBLISHED: Insulin Resistance Does Not Impair Mechanical Overload-Stimulated Glucose Uptake, but Does Alter the Metabolic Fate of Glucose in Mouse Muscle

Abstract Skeletal muscle glucose uptake and glucose metabolism are impaired in insulin resistance. Mechanical overload stimulates glucose uptake into insulin-resistant muscle; yet the mechanisms underlying this beneficial effect remain...

June 24, 2020

IBRI RESEARCH PUBLISHED: Adiponectin receptor fragmentation in mouse models of type 1 and type 2 diabetes

Abstract The protein hormone adiponectin regulates glucose and fatty acid metabolism by binding to two PAQR-family receptors (AdipoR1 and AdipoR2). Both receptors feature a C-terminal segment which is released...

June 15, 2020

IBRI IN THE NEWS: Biosciences Institute Develops Diagnosis Technologies

INDIANAPOLIS - The Indiana Biosciences Research Institute in Indianapolis has completed development of two technologies it says could diagnose diseases faster and with more accuracy. The IBRI says its BioMEMs...

June 11, 2020

IBRI Develops Technologies that Help to Diagnose Diseases Faster, More Accurately

INDIANAPOLIS, IND. - The Indiana Biosciences Research Institute (IBRI), a leading independent, industry-inspired applied research institute, is pleased to announce that it has completed development of two technologies – BioMEMs...

June 09, 2020

IBRI and TBH Creative Win Gold Aster Award

We were pleased to partner with TBH Creative to move our 2018 Annual Report from print to online. TBH Creative took the PDF and transformed it into its own microsite...

June 03, 2020

IBRI RESEARCH PUBLISHED: Pre-clinical Evaluation of TYK2 Inhibitors for Human Beta Cell Protection in Type 1 Diabetes

Abstract: Aims: Type 1 diabetes (T1D) is a chronic autoimmune disease leading to progressive loss of pancreatic beta cells. Interferon (IFN)-α plays a critical role in the crosstalk between...

May 29, 2020

IBRI IN THE NEWS: Pushing Hard for a COVID-19 Vaccine

The race is on. Around the world, more than 80 vaccine projects are under development by pharmaceutical companies and university research laboratories scrambling to find a way to slow...

May 26, 2020

New Research Identifies Two Classes of Drugs that Could be Re-purposed for the Early Treatment of T1D

INDIANAPOLIS - Researchers from the Indiana Biosciences Research Institute (IBRI), a leading independent, industry-inspired applied research institute, and Université Libre de Bruxelles (ULB) Center for Diabetes Research, identified two classes...

 1 2 3 4 5  ... Last 
2019 Annual Report cover

The IBRI 2019 Annual Report is now available. The report theme is “Catalyze, Complement, Connect,” which correlates with the IBRI's goals to seek solutions for health problems, enhance the Indiana life sciences ecosystem, and expedite solutions for the most pressing health issues.